Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Products to launch on Sephora.co.uk

10 May 2023 07:00

RNS Number : 8579Y
Cellular Goods PLC
10 May 2023
 

Press release

 

10 May 2023

 

 

Cellular Goods PLC

 

('Cellular Goods' or 'the Company')

 

Products to launch on Sephora.co.uk

 

Cellular Goods (LSE: CBX), a UK-based skincare and wellness company providing premium consumer products formulated with lab-produced cannabinoids, is pleased to announce that it has entered into a contract with multinational beauty and cosmetics retailer Sephora to make the Company's 'Look Better' (skincare) range available for purchase on Sephora's e-commerce website, Sephora.co.uk from the second half of May.

 

Cellular Goods will become the first cannabigerol (CBG)-based skincare brand to offer its products on Sephora UK, as part of the Company's enhanced retail strategy to drive growth by expanding its sales channels and increasing its collaboration with established online and high street outlets.

 

Sephora.co.uk will stock the full range of the Company's facial skincare products including the brand's best-selling Rejuvenating Face Serum, designed to visibly reverse signs of skin ageing, whilst also protecting from inflammation and irritation. Cellular Goods' newest range of skincare products, the Rejuvenating Night Cream, SPF 25 Rejuvenating Day Cream and Rejuvenating Day Mousse, containing the Company's proprietary formulation of CBG and CBD, will also be available on the website.

 

Additional Cellular Goods products available on Sephora.co.uk include the Company's CBG-based Nourishing Cannabinoid Face Oil, and Calming Cannabinoid After Shaving Moisturiser, as well as selected 'mini' sizes and gifting products during seasonal moments.

 

Darcy Taylor, Chairman and Interim CEO of Cellular Goods, commented: "I'm delighted that our products will be going on sale at Sephora.co.uk. The launch bridges the gap between customer awareness and sales by making it easier for customers to purchase our products. We're confident that our effective next-generation skincare formulations will appeal to their existing customers and encourage them to try our CBG-powered products. The Sephora launch is part of our continued customer acquisition strategy, as we continue to increase awareness of our products and grow our sales channels."

 

For further information please contact:

Cellular Goods

Darcy Taylor

Chairman and interim CEO

Neil Thapar

Investor Relations

via Tancredi +44 207 887 7633

 

+44 787 645 5323

First Sentinel Corporate Finance

Corporate Broker & Advisor

Brian Stockbridge

 

+44 7876 888 011

Novum Securities

 

Corporate Broker

Colin Rowbury

Jon Belliss

 

 

+44 207 399 9427

Tancredi Intelligent Communication

Media Relations

Helen Humphrey

Charlie Hobbs

cellulargoods@tancredigroup.com

 

+44 744 922 6720

+44 789 755 7112

 

About Cellular Goods PLC:

Cellular Goods develops and markets premium quality skincare and wellness products based on proprietary formulations incorporating biosynthetic lab-made cannabinoids. Our branded products are efficacy-led and research-backed and available online in the UK and US. The Company is incorporated in the UK and listed on the Main Market of the London Stock Exchange. For more information, visit www.cellular-goods.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PRLSSIFAUEDSESI
Date   Source Headline
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 202211:00 amRNSPrice Monitoring Extension
22nd Mar 20227:00 amRNSDirectorate change
14th Mar 20224:41 pmRNSSecond Price Monitoring Extn
14th Mar 20224:36 pmRNSPrice Monitoring Extension
14th Mar 20222:05 pmRNSSecond Price Monitoring Extn
14th Mar 20222:00 pmRNSPrice Monitoring Extension
14th Mar 20227:00 amRNSLaunch of outdoor marketing campaign
8th Mar 202211:03 amRNSShare purchase by CEO
7th Mar 202211:05 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
4th Mar 20224:41 pmRNSSecond Price Monitoring Extn
4th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSExercise of Warrants
1st Mar 20227:00 amRNSLaunch of Rejuvenating Cannabinoid Face Serum
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
23rd Feb 20222:06 pmRNSSecond Price Monitoring Extn
23rd Feb 20222:01 pmRNSPrice Monitoring Extension
21st Feb 202211:05 amRNSSecond Price Monitoring Extn
21st Feb 202211:00 amRNSPrice Monitoring Extension
21st Feb 20229:05 amRNSSecond Price Monitoring Extn
21st Feb 20229:00 amRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSStrategy and trading update
2nd Feb 20227:00 amRNSWhite paper on cannabinoids and skin aging
7th Jan 20221:00 pmRNSResults of Annual General Meeting
15th Dec 20217:00 amRNSAnnual General Meeting update
8th Dec 20217:00 amRNSGrant of Options to CEO
6th Dec 20211:57 pmRNSPosting of Annual Report and Notice of AGM
6th Dec 20217:00 amRNSAppointment of new CEO
3rd Dec 20217:00 amRNSAnnual results
1st Dec 20217:00 amRNSLaunch of inaugural products & ecommerce platform
11th Nov 20217:00 amRNSAdvertising and PR agencies appointed
8th Nov 20212:05 pmRNSSecond Price Monitoring Extn
8th Nov 20212:00 pmRNSPrice Monitoring Extension
8th Nov 202111:05 amRNSSecond Price Monitoring Extn
8th Nov 202111:00 amRNSPrice Monitoring Extension
1st Nov 20217:00 amRNSGrant of Share Options and update on warrants
4th Oct 20219:06 amRNSSecond Price Monitoring Extn
4th Oct 20219:00 amRNSPrice Monitoring Extension
4th Oct 20217:00 amRNSDirector dealings & TR1 notification
16th Aug 20217:00 amRNSSupply agreement signed with Chanelle McCoy Health
2nd Aug 20217:00 amRNSShare disposal by significant shareholder
28th Jul 20212:06 pmRNSSecond Price Monitoring Extn
28th Jul 20212:00 pmRNSPrice Monitoring Extension
10th Jun 20217:00 amRNSSupply agreement signed with Willow Biosciences
25th May 20217:00 amRNSCellular Goods Interim Results
6th May 20217:00 amRNSGrant of Warrants and Extension of Exercise Period
20th Apr 20212:00 pmRNSPrice Monitoring Extension
12th Apr 20217:00 amRNSCellular Goods boosts team with five appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.